

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934**

Dated June 9, 2016

Commission File Number 001-36421

AURINIA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant's Name)

#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250) 708-4272
(Address and telephone number of registrant's principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 9, 2016.

Aurinia Pharmaceuticals Inc.

By: /s/ Dennis Bourgeault _____

Name: Dennis Bourgeault

Title: Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	News Release – Aurinia Announces Results of Annual General Meeting
99.2	Report of Voting Results

Aurinia Announces Results of Annual General Meeting

VICTORIA, British Columbia--(BUSINESS WIRE)--June 9, 2016--Aurinia Pharmaceuticals Inc. (“**Aurinia**” or the “**Company**”) (NASDAQ: AUPH / TSX: AUP) is pleased to announce that the six incumbent directors of the Company were re-elected at the Company’s annual general meeting held on June 8, 2016 (the “**Meeting**”).

Results of the vote by proxy for the election of directors are provided below:

Nominee	Votes For (%)	Votes Withheld (%)
Election of Directors		
Richard Glickman	99.89%	0.11%
Charles Rowland Jr.	99.72%	0.28%
Benjamin Rovinski	99.89%	0.11%
David Jayne	99.89%	0.11%
Gregory Ayers	99.89%	0.11%
Hyuek Joon Lee	99.88%	0.12%

Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.

About Aurinia

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. The fully-enrolled Phase 2b AURA-LV clinical trial is evaluating the efficacy of its lead drug, voclosporin, as a treatment for active lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

About AURA

The AURA-LV study or “Aurinia Urine Protein Reduction in Active Lupus Nephritis Study” is an adequate and well-controlled clinical trial that enrolled 265 patients and is being conducted in over 20 countries worldwide. This trial will compare the efficacy of voclosporin against placebo in achieving remission in patients with active lupus nephritis. The AURA-LV study is designed to demonstrate that voclosporin can induce a rapid and sustained reduction of proteinuria in the presence of extremely low steroid exposure. It will compare two dosage groups of voclosporin (23.7mg and 39.5mg) compared to placebo, with all patients receiving mycophenolate mofetil (“MMF”) and oral corticosteroids as background therapy. There will be a primary analysis to determine complete remission at week 24 (confirmed at 26 weeks) and various secondary analyses at week 48 which include biomarkers and markers of non-renal SLE.

We seek Safe Harbor.

CONTACT:

Aurinia Pharmaceuticals Inc.
Michael R. Martin, 250-708-4272
Chief Operating Officer
mmartin@auriniapharma.com

or
Renmark Financial Communications Inc.
Barry Mire, 416-644-2020
bmire@renmarkfinancial.com

or
Laura Welsh, 514-939-3989
lwelsh@renmarkfinancial.com

AURINIA PHARMACEUTICALS INC.

Report of Voting Results

This report is filed pursuant to Section 11.3 of National Instrument 51-102 and relates to the results of voting at the annual general meeting of Aurinia Pharmaceuticals Inc. (the "Company") held on June 8, 2016.

Description of Matter

Resolution to fix the number of directors at six (6).

Resolution to elect the management nominees as directors of the Company.

Resolution to appoint PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors of the Company until its next annual general meeting, at a remuneration to be fixed by the directors.

Outcome of Vote

Resolution passed by requisite majority.

Details of the voting by proxy are as follows:

Total shares voted in favour: 16,756,688 (99.65%)

Total shares voted against: 5,916 (0.35%)

All nominees proposed by management were elected to serve as directors of the Company until its next annual general meeting.

Details of the voting by proxy are as follows:

Name	Votes in Favour	Votes Withheld
Richard Glickman	14,746,357 (99.89%)	15,802 (0.11%)
Charles Rowland Jr.	14,720,392 (99.72%)	41,767 (0.28%)
Benjamin Rovinski	14,745,707 (99.89%)	16,452 (0.11%)
David Jayne	14,745,559 (99.89%)	16,600 (0.11%)
Gregory Ayers	14,745,749 (99.89%)	16,410 (0.11%)
Hyuek Joon Lee	14,744,308 (99.88%)	17,851 (0.12%)

Resolution passed by requisite majority.

Details of the voting by proxy are as follows:

Total shares voted in favour: 16,808,799 (99.96%)

Total shares withheld: 6,997 (0.04%)

Resolution to approve the amendment to the Company's stock option plan.

Resolution passed by requisite majority.

Details of the voting by ballot are as follows:

Total shares voted in favour: 11,081,418 (75.07%)

Total shares voted against: 3,680,961 (24.93%)

DATED this 9th day of June, 2016

AURINIA PHARMACEUTICALS INC.

By: /s/ Dennis Bourgeault
Name: Dennis Bourgeault
Title: Chief Financial Officer